Aims The adverse prognostic significance of biomarker elevations after percutaneous coronary intervention (PCI) is well established. However, often baseline troponin values are not included in the analysis or sensitive criteria are not employed. Accordingly, we assessed the timing and magnitude of post-PCI troponin T (cTnT) levels and their relationships to outcomes in patients with and without pre-PCI baseline cTnT elevations using a sensitive assay and sensitive cut-off values. Methods and results cTnT was measured at baseline (pre-PCI), 8 and 16 h post-PCI in 2352 patients. A cTnT elevation was defined as 0.03 ng/mL. No baseline cTnT elevations were detected in 1619 patients undergoing mostly (97%) non-urgent procedures (cTnT ¼ 0.01 + 0.002 ng/mL; mean + SD). 733 patients had baseline cTnT elevations. Only the baseline troponin value had prognostic importance. Patients with elevated cTnT baseline levels had a higher overall cumulative 12-month death/MI rate of 11.1% compared with those without elevated baseline levels of 4.7% (P , 0.05). Neither the timing nor the magnitude of the post-procedure cTnT elevations was predictive of long-term death/MI rates when baseline elevations were included in the analysis. Similar findings were observed for baseline creatine kinase-MB (CK-MB) levels. Late increases in cTnT levels (16 h post-PCI) presaged in-hospital events only. Conclusion Long-term prognosis is most often related to the baseline pre-PCI troponin value and not the biomarker response to the PCI. These results support a re-evaluation of the use of biomarker data in relation to PCI.
Introduction
The adverse prognostic significance of myocardial biomarker elevations after catheter-based coronary interventions (percutaneous coronary intervention, PCI) is well established. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] However, the amount of injury in most cases is modest making it unlikely that prognosis is related to the extent of PCI-related injury. Thus, the mechanism for this effect is unknown. It has been suggested that elevations may reflect the extent of coronary artery disease, embolic events, stent expansion, or the lack of collateral perfusion to the area at risk [12] [13] [14] [15] [16] [17] as possible mechanisms of risk. However, some of these findings antedate the intervention and may be identifiable in many patients by baseline (preprocedure) elevations in troponin. Elevations of troponin are known markers of unstable, extensive, and complex thrombotic coronary artery disease, and herald an adverse prognosis in patients with acute coronary syndromes. 8, 18, 19 Most PCI outcome studies have not included the baseline troponin level as a co-variant and even when it has been measured and included in the analysis, low cut-off values that maximize prognostication have not been used. 1, 7, [9] [10] [11] [20] [21] [22] [23] [24] [25] [26] Accordingly, we evaluated consecutive patients enrolled in the Mayo Clinic PCI database to assess the influence of baseline troponin values using low and thus highly sensitive cut-off values and subsequent elevations of troponin after PCI on outcomes. In addition, we investigated whether the timing of troponin elevations post-PCI and the relationship between baseline troponin elevations and post-PCI creatine kinase-MB (CK-MB) mass elevations were of importance.
Methods
A consecutive cohort of patients (n ¼ 2352) referred for elective or urgent (within 24-48 h of evaluation) coronary angiography and PCI with the diagnosis of progressive symptomatic coronary artery disease or acute coronary syndrome were studied prospectively. This group came from the total of 3321 PCIs done during the period August 1, 2000 to August 31, 2002 . Five hundred and ninety-six were excluded because they had ST segment elevation acute myocardial infarctions. Of the remaining 2725 PCI, 86 (3.2%) were excluded because of the absence of a baseline troponin sample. Patients having baseline measurements but lacking complete post-PCI samples were not excluded (n ¼ 40). Thus, there remained 2639 procedures done on 2352 unique patients. We included only the earliest PCI per patient in the analysis.
Blood was drawn to measure cardiac troponin T (cTnT) and CK-MB mass at baseline (maximum of 72 h pre-procedure), 8 and 16 h post-PCI. An elevated cTnT was defined as a value 0.03 ng/mL per ESC/ ACC guidelines 27, 28 and an elevated CK-MB mass was defined as 6.2 ng/mL. 27, 28 Patient data and follow-up were available via the Mayo percutaneous transluminal coronary angioplasty (PTCA) registry, a prospectively collected database. Patients were contacted by phone at 6 and 12 months post-PCI and yearly thereafter. At the time of the phone interview, the patients were asked about symptoms and hospitalization. If hospitalizations had occurred, we would review the records from that hospitalization after obtaining consent from the patient. If the patient was deceased, we would obtained from family members the date of death and cause of death if available. All patients who undergo PCI at our institution are followed-up by the same protocol and no patients were excluded because of lack of follow-up.
Integrilin or abciximab were most commonly used in conjunction with interventions when deemed clinically indicated. Standard recommended doses were used for 12-24 h post-PCI. All patients received aspirin (325 mg) before the intervention and patients receiving stent implantation received clopidogrel (300 mg) prior to stent placement. Subsequently, biomarker levels were determined at each predetermined time interval. cTnT assays were performed using a highly sensitive and precise third generation assay (Elecsys, Roche Diagnostics, Indianapolis, IN, USA). The cTnT assay has a coefficient of variability of 10% at a value of 0.035 ng/mL and 20% at 0.015 ng/mL. The limit of detection is 0.01 ng/mL. CK-MB mass was also measured on the Elecsys analyzer. This investigation was approved by the Mayo Foundation Institutional Review Board and included only patients who gave informed consent for research analysis as required by Minnesota Statute 144.335/ CRF 21 (Part 50).
Statistical analysis
Continuous data are presented as mean + standard deviation and compared using one-way analysis of variance (unless otherwise noted). Frequencies and percentages are used to summarize discrete variables, which are compared using Pearson's chisquared test for nominal data and the Wilcoxon rank-sum test for ordinal data. In addition, higher cut-off values such as 0.10 ng/mL for cTnT were explored for both the pre-and post-PCI values. The date of discharge marked the beginning of the follow-up period. Kaplan-Meier methods were used to estimate survival rates. A significance level of ,0.05 was used. All tests were two-sided. As this study is hypothesis generating, we have not adjusted any P-values for multiple hypothesis tests. Cox regression models (both simple and multivariable) were used to estimate hazard ratios. Multivariable regression models included variables typically associated with adverse events in this patient population. 9 Biomarker levels were then added to the model. Biomarker values were log-transformed (base 2) to account for their skewed distribution and used as continuous variables. Thus, the resulting hazard ratios reflect the effect of a doubling in the biomarker. Linearity was assessed by visually inspecting Martingale residuals from an intercept only model against the logged troponin measures. There was no evidence of a need for a non-linear functional form. Proportional hazards assumptions were assessed by tests and plots based on weighted residuals. 29 A likelihood ratio test was used to compare a model with only the baseline biomarker to a model with baseline, 8 and 16 h biomarkers (plus interactions between baseline and the two later measures). In this way, the additional prognostic information of the later biomarkers was assessed.
Results
The baseline clinical characteristics of the 2352 patients included in the study with and without baseline elevations in cTnT are shown in Table 1 . Those with cTnT elevations had more severe disease. The procedural treatment profile of patients undergoing PCI is also shown in Table 1 . Sixtyfive percent of these patients received IIb/IIIa inhibitor therapy. In 58% of patients, the procedure involved PTCA þ stent placement, 11% underwent PTCA only, and 31% had stent placement only. There was no difference in the type of intervention used in patients with and without baseline (3) 150 (81) cTnT elevations. More patients with baseline elevations in cTnT level underwent non-elective (PCI within 24-48 h of assessment) procedures than those without baseline elevation in cTnT (81 vs. 3%, P , 0.001).
Post-PCI elevations
Early (8 h) cTnT peaks post-PCI were less common than late (16 h) peaks (15 vs. 42%, P , 0.001) but tended to be of higher magnitude regardless of an elevated or normal pre-PCI cTnT level. When the baseline cTnT level was elevated, the frequency of peak elevations at 8 h was much greater (38 vs. 4%). Table 2 shows the values for cTnT and CK-MB at baseline and post-PCI based upon the presence or absence of pre-procedural elevation in cTnT. Patients with baseline elevations in cTnT had significantly higher values of both cTnT and CK-MB post-PCI. Post-PCI elevations of CK-MB (6.2 ng/mL) were much more frequent when the baseline cTnT was elevated. In patients without baseline elevation in cTnT, 10.1% had an elevated CK-MB at 8 h and 21.4% at 16 h post-procedure ( Table 3) . If cTnT level was elevated at baseline, many more patients had CK-MB elevations early after PCI (49.9% had CK-MB elevations at 8 h and 52.3% at 16 h, P , 0.001). Overall, including elevations at both 8 and 16 h, 54% of patients with post-PCI elevations of CK-MB also had elevated baseline cTnT values.
Patients with normal baseline cTnT (<0.03 ng/mL) Table 4 shows patient and procedure profiles for patients without baseline cTnT elevations (,0.03 ng/mL). Patients without changes in cTnT from baseline post-PCI were compared with those who had peak elevations at 8 and 16 h post-PCI. Troponin levels were not elevated at baseline in 1619 patients undergoing mostly (97%) non-urgent procedures (cTnT ¼ 0.01 + 0.002 ng/mL, mean + SD). Of these patients, 1396 had complete biomarker data (preprocedure baseline, 8 or 16 h post-procedure) and thrombolysis in myocardial infarction (TIMI) grade 3 coronary blood flow post-procedure. No post-PCI cTnT elevations occurred in 756 (54%) patients. Sixty-two (5%) had peak values at 8 h (0.55 + 1.96 ng/mL) and 578 (41%) had cTnT peaks at 16 h post-PCI (0.17 + 0.36 ng/mL). GP IIb/IIIa inhibitors were more frequently used in those patients with post-PCI elevations in cTnT (66%) than those without elevations (55%, P , 0.001). These patients did, however, also have more extensive coronary artery disease. Early cTnT peaks (8 h post-procedure) were not associated with a greater risk of long-term outcome of death/MI after multivariable correction when troponin was used as a continuous variable. When modelled at a higher cut-off value of 0.1 ng/mL, the HR was 2.21; CI 1.1-4.6; P ¼ 0.034.
Late elevations in cTnT (16 h post-PCI) were associated with an overall increase in-hospital death/MI rate but not long-term events ( Table 5 ; median follow-up 11.9 months). This likely reflects the acute result of the procedure itself, as when inhospital events ,24 h post-procedure were excluded, 16 h elevations in cTnT were no longer predictive of in-hospital death/MI (P ¼ 0.12; Table 5 ). There was no difference in long-term survival whether post-PCI cTnT levels were elevated above baseline or not ( Figure 1 ; P ¼ 0.37).
Patients with elevated baseline cTnT (0.03 ng/mL) Table 6 shows the patient and procedure characteristics of the patients (n ¼ 733) with baseline elevations of cTnT 0.03 ng/mL (mean ¼ 0.58 + 1.03 ng/mL). Of the 603 patients with complete biomarker data (pre-procedure baseline, 8 and 16 h post-procedure) and demonstrated TIMI grade 3 coronary blood flow post-procedure, 119 (20%) had no further elevations of cTnT above the baseline level. Of the remaining patients, 231 (38%) demonstrated increased peak levels at 8 h (1.66 + 2.24 ng/mL) and 253 (42%) at 16 h (0.87 + 1.34 ng/mL) post-PCI. GP IIb/IIIa inhibitors were used more often in patients having postprocedure elevations above baseline in cTnT (77 vs. 62%, P , 0.001). The extent of CAD was not different among the three patient groups. In those patients with elevated cTnT at baseline (0.03 ng/mL), late peak increases (16 h) but not early (8 h) peaks post-PCI were associated with increased (P , 0.001) in-hospital events of death/MI ( Table 7) . These likely reflect events during the procedure 16 h cTnT peak (n ¼ 578)
P-value
In-hospital death, n (%) 0 itself, as most of these events occurred during the initial 24 h post-procedure. Neither 8 h nor 16 h peak increases were associated with a further increased risk of long-term events over and above the baseline elevation, even when only higher cTnT levels 0.1 ng/mL were used in the analyses (HR 1.12; CI 0.6-2.2; P ¼ 0.74). No difference in long-term survival was evident when patients with and without post-PCI cTnT levels above baseline were compared ( Figure 2 ; P ¼ 0.22).
Prognostic value of baseline vs. post-PCI cTnT elevation
Models with all three cTnT measures (baseline, 8 h, 16 h) did no better than baseline cTnT only models for both follow-up death (P ¼ 0.18) and death or MI (P ¼ 0.16). The baseline cTnT alone was significantly associated with follow-up events, even when adjusting for other risk factors ( Table 8) . Inclusion of the baseline cTnT values had a similar effect on post-PCI CK-MB mass values. In addition, similar to the prognostic value of baseline cTnT level, an elevated baseline CK-MB level was also shown to be predictive of death/MI (HR 1.12; CI 1.02-1.22, P ¼ 0.015; Table 9 ).
Discussion
These data extend our understanding of post-PCI elevations in biomarkers. Our data show that it is the baseline elevations of cTnT which can be detected with sensitive assays and sensitive criteria that are predictive of events. When added to the analysis, post-PCI elevations of cTnT no longer have impact ( Table 8 ). The same is true for post-PCI elevations of CK-MB. These effects may not be detected at baseline by CK-MB because of its limited sensitivity when compared with troponin. Only one other recent study has addressed this issue with sensitive troponin assays and sensitive cut-off values and made a similar point concerning the need for baseline values but lacked outcome data. 30 
Patients with elevated baseline cTnT values
Elevated baseline cTnT levels predicted a high cumulative 12-month death/MI rate of 11.1 vs. 4.7%, (P , 0.05). Those with elevated baseline cTnT but no further increase post-PCI did comparatively well with a 7% death/MI rate at 12 months post-procedure but this was still nearly double the 4% event rate in those patients without baseline elevations and no post-PCI cTnT elevations. This trend did not reach statistical significance. These data suggest that the elevations in cTnT at baseline reflect the major cause of adverse prognosis seen in these patients and that additional values of cTnT and/or CK-MB do not add to that analysis. A similar trend was present for CK-MB but because of its reduced sensitivity compared with cTnT, a much smaller number of patients were involved. Our data can neither define the mechanisms nor identify those patients who have post-PCI elevations due to rising levels at the time of PCI or who are simply marked as being at greater risk for cardiac injury by the baseline elevation. In patients with ACS, many of whom are included in this analysis, cTnT elevations at baseline (pre-procedure) are commonly associated with more diffuse coronary artery disease, increased thrombus, reduced TIMI flow grades, less collateral flow, and an adverse prognosis. In addition, these patients respond with an improved prognosis to more aggressive anti-coagulant therapies and an early invasive strategy [31] [32] [33] [34] as is the practice at our institution. The principles articulated should be applicable with most troponin assays but the cut-off values that are needed will obviously vary with the assay used. 
P-value
In-hospital death, n (%) 0 (0) 0 (0) 3 (1) 0.10 In-hospital death .24 h post-procedure, n (%) 0 (0) 0 (0) 3 (1) 0.10 In-hospital any MI, n (%)
3 (3) 6 (2) 25 (10) ,0.001 In-hospital any MI .24 h post-procedure, n (%) 1 (1) 0 (0) 3 (1) 0.23 In-hospital death/any MI, n (%)
3 (3) 6 (2) 28 (11) ,0.001 In-hospital death/MI .24 h post-procedure, n (%) 1 (1) 0 (0) 6 (2) 0.035 In-hospital death/MI/CABG/Redo PCI, n (%)
4 (3) 6 (2) 28 (11) ,0.001 In-hospital death/MI/target revascularization .24 h post-procedure, n (%) The magnitude of peak cTnT elevations post-PCI, which has been suggested to be an adverse prognostic signal in many data sets, 7, [20] [21] [22] [23] 25, 26 did not improve prognostication when the baseline troponin was elevated nor did it matter whether peak elevations were seen at 8 or 16 h except for the association of in-hospital complications when peak values occurred at 16 h.
These findings do not indicate that cardiac injury cannot occur during PCI when baseline values are elevated, only that their frequency and/or magnitude are insufficient to influence the prognosis of the cohort. These data do suggest, however, that the monitoring of post-PCI biomarkers when the baseline troponin is elevated may not be necessary.
Patients with normal baseline cTnT values
In this subset, the results are only slightly different. Peak elevations tended to occur late rather than early. Early elevations were uncommon and had no prognostic significance. When a cut-off value of 0.1 ng/mL was used, the P-value appeared to be significant. However, the fact that elevations could not be confirmed to be prognostic using continuous data makes this likely a statistical artefact related to multiple testing. When peak elevations occurred at 16 h post-PCI, as was more common in the group with normal baseline values, there was an association with elevations in in-hospital complications only.
CK-MB analysis
Baseline cTnT elevations also obviated the prognostic significance of post-PCI CK-MB elevations. The presence of CK-MB elevations was highly associated with baseline elevations of cTnT, but showed weaker prognostic value for long-term death/MI rates. Fifty-nine percent of those with post-PCI CK-MB elevations had baseline cTnT elevations and the magnitude of the CK-BM elevations was substantially greater and the timing was earlier (mean 7.42 ng/mL compared with 65.8 ng/mL for those peaking at 8 h and 9.79 ng/mL compared with 25.3 ng/mL for those peaking at 16 h). Nearly 50% of elevations occurred at 8 h, whereas in the absence of a baseline cTnT elevation, there was a 2:1 preponderance of late elevations. It may be that especially early elevations represent continued release of CK-MB in response to the initiating event that led to the need for PCI which was detected by the greater sensitivity of cTnT. In previous trials in which post-PCI values were found to be prognostic, there was invariably a gradient of risk with higher values being associated with greater risk. 1, 10, 11, 35, 36 When baseline values for cTnT were included, a high cut-off value was often employed. 1, 20, 23, 25, 26, [37] [38] [39] [40] [41] [42] [43] If as suggested by our data, these post-PCI elevations were related to elevations in the baseline cTnT measurements, then assessment of post-PCI values may not be needed. Our data may also explain the confusion regarding the mechanisms involved which have been elusive and controversial. 1, 3, 5, 18, 19, 27, 28 
Implications
The practical clinical implications of these data for the diagnosis of post-PCI cardiac injury are significant. These findings question the utility of monitoring biomarkers post-PCI when the initial cTnT value is elevated. If confirmed in other data sets, these data would suggest that the routine monitoring of biomarkers post-PCI is not warranted to define short-and/or long-term prognosis if the baseline cTnT value is elevated. Looking for peak increases at 16 h may help to define in-hospital complications if not clinically overt. Although CK-MB values may more often be normal, they lack the sensitivity to be used in such a manner. It could be argued that such an approach should be extended to all patients who present acutely even if the initial cTnT value is not elevated, as it may be too early in some patients to know whether the value will be elevated. Absent an elevated baseline value, post-PCI values may be of value because elevations do correlate with in-hospital events when peak values occur at 16 h post-PCI. These data would also suggest a need to re-evaluate those therapeutic studies that have targeted the elimination of post-PCI biomarker elevations as a goal. Most data suggest that such interventions are far more effective in individuals who demonstrate elevated cTnT values at baseline. 32, 33, 44, 45 In conclusion, our data show for the first time that the presence and the degree of cTnT elevations pre-PCI are what predicts long-term events rather than the biomarker response to the PCI. On the basis of our data, re-evaluation of how biomarker data are used to assess prognosis in patients who undergo PCI seems warranted. 
